Antimicrobial Resistance (AMR) results when microorganisms including bacteria, fungi, parasites and viruses evolve to the extent that they eventually become resistant to the antimicrobial medications, such as antibiotics, which are used to treat such conditions [1]. AMR has now emerged to be one of the greatest global concerns in the 21st century due to the rapid growth of AMR infections rate and the lack of new antimicrobial medications being introduced to combat this issue [2]. One of the main causes of the current issue could be the consequences of overuse or irresponsible use of antibiotics in various situations, primarily in clinical treatment along with agricultural usage, animal healthcare and the food system [3]. AMR is widely referred to as the “Silent Pandemic” and is a problem where urgent action is needed immediately and should be managed more effectively and not be considered as a future situation [4].

Without preventative measures, it is estimated that by 2050, AMR could potentially become the world’s primary cause of death [5]. According to estimates provided globally, the number of deaths directly linked to AMR has risen to more than 1.2 million in 2019 and this is forecast to increase to approximately 10 million deaths per year by 2050, if insufficient action is taken to control AMR [5].

In response to AMR, several global health organisations and governments have taken action to combat this issue. The “One Health Approach” was introduced which requires a global collaborative effort to involve a number of different disciplines: the Food and Agriculture Organization of the United Nations (FAO) and the World Organization of Animal Health (OIE), to ensure that each agency works within its speciality and with other agencies to minimise the potential effects of AMR [6]. In addition, the World Health Organization (WHO) has established the Global Action Plan for managing AMR (GAP-AMR) followed by launching the Global Antimicrobial Resistance and Use Surveillance System (GLASS) to continuously close the existing knowledge gaps in order to achieve the goals of GAP-AMR programme [7].

Within most of these newly proposed measures, one of the most effective approaches is to increase public awareness of the AMR pandemic as a preventative strategy, thereby requiring good communication with all stakeholders [8]. In this review, the aim is to examine the various current global AMR management strategies, to aid its control.

The creation of antimicrobials is one of the most effective drug treatments in medical history. The introduction of antimicrobials has helped to manage and greatly reduce death rates caused by infectious diseases, previously the leading cause of death in humans [9]. Human life expectancy has increased on average by 23 years, since the first antibiotic was introduced in 1910 [10]. With regard to that, the discovery of the antibiotic penicillin, by Sir Alexander Fleming was one of the greatest medical advancements of the 20th century which initiated the “golden era” of antibiotics [10]. However, shortly after, the production of penicillinase by antibiotic-resistant strains was reported, which led to inactivation of the antibiotic molecule, thereby rendering it clinically ineffective [11]. This is important to note, as penicillin and its derivatives (cephalosporins, carbepenems) are the major class of antibiotics still employed today, in treating human and animal infections. Over 150 new antibiotics have been developed since then and their widespread usage and overusage has led to the development of higher resistance and even multiresistant forms of the so-called “superbugs.” These have increased mortality rates due to a lack of clinical effectiveness, resulting from antibiotic use/misuse [11]. AMR is the term given to this resistance, which has been discovered in viruses, parasites, fungi, and bacteria. However, with regards to AMR, bacterial antibiotic resistance is particularly problematic due to its rapid rate of developing resistance to many new antibiotics, which are used to treat bacterial infections (Figure 1) [2].

Previous research has shown that one of the main causes of AMR is the inappropriate and excessive use of antibiotics, both in humans, as well as in animals. Since the 1950s, when the “golden era” of antibiotics began, Alexander Fleming had expressed concerns about the potential emergence of resistance if treatment is used for an inadequate amount of time [13]. “Since then, there has been an increasing demand for new and novel antibiotics, in order to combat highly resistant strains that have been emerging.”

As a result, the use of antibiotics in treating infectious diseases and other conditions has become widespread in modern medicine. Nevertheless, the misuse and even over-prescription of these antimicrobials has fast outpaced their efficacy as AMR has grown markedly [10].

A series of recent studies have indicated antimicrobial involvement in agriculture and food systems may have a significant impact on driving AMR [14]. According to estimates, in the US, 70% of antibiotics used to treat humans are available for use in veterinary medicine [15]. In recognising such high usage in global agriculture, several organisations, including the World Health Organization (WHO), the United Nations (UN) and the European Union (EU) have taken steps towards reducing and restricting the use of antimicrobials in animals, through the legislative banning of using certain antibiotics in agrifood systems for growth promotion, as well as promoting antimicrobial stewardship initiatives in treating food animals, as well as in small domestic companion animals. Such controls may be difficult to implement particularly in developing countries where the demands for food animals continue to rise annually [16].

In addition, zoonosis also poses a serious transmission factor of AMR, where antibiotic-resistant bacteria are spread between animals and humans, through either direct or indirect interaction, as well as through foodborne or waterborne events [17, 18].

A study conducted in China has reported that mediated colistin resistance (MCR-1) poses a high risk to AMR due to zoonosis transmission from animal to human [19]. According to this study, MCR-1 was detected in E. coli isolates from animal and commercial meat sources and MCR-1 is believed to have been widely transmitted in food-producing animals in south China. In contrast, relatively low MCR-1 was detected from human origin, this difference in the prevalence of MCR-1 between animals and humans is likely to be a form of zoonotic transmission from animals to humans [19].

Colistin is regarded as a “last resort” antibiotic that is increasingly being utilised to treat patients with multiresistant bacteria, although it is still effective it was not typically used to treat common infections due to its potentially adverse side effects. However, if colistin resistance evolves rapidly, these bacterial infections may be more difficult-to-treat [20].

The lack of knowledge of antimicrobials is also a major contributing factor to AMR. Public Health England conducted a UK survey in 2017 to find out public knowledge on antibiotics [21]. Eighty three percent of participants admitted that antibiotics could be used to treat bacteria and 35% of participants believed that antibiotics could be used to treat viral infections. These results have improved since the survey that was conducted in 2014, which indicates that the public in the UK has become more informed and educated about antibiotics [21]. In comparison to a survey conducted in India, it was found that 49% of the respondents stated that antibiotics could treat viral infections and 45% of respondents use antibiotics for treating colds [22]. As a consequence, India was reported as having one of the highest rates of infectious disease, including those caused by multi-resistant pathogens [23]. These studies indicate that there is a relationship between AMR and public awareness.

With AMR emerging at a rapid rate, the infection and death rates of AMR are closely monitored at all times. In the United Kingdom, the estimated AMR infection rate was 65,162 people diagnosed in 2019, which increased from 61,946 patients recorded in 2018 [24]. In comparison, the European Centre for Disease Prevention and Control (ECDC) has reported in the EU alone, the infection rate of AMR has reached over 670,000 cases annually [25]. According to data analysis from a prior study, there were 4.95 million deaths worldwide in 2019 that were linked to bacterial AMR, and 1.27 million of those deaths were directly caused by bacterial AMR [26]. In a well-known review, it was previously reported that the annual death rate directly caused by AMR is predicted to rise to 10 million by 2050. With the highest estimated deaths of this being in Asia followed by Africa, mainly due large populations and lack of regulation associated with AMR prevention [5]. According to previous research, Sub-Saharan Africa has the highest all-age mortality rate in the Global Burden of Diseases (GBD) region that is directly linked to or related to AMR, in contrast to Australasia which had the lowest rate of AMR-related mortality in 2019 [26].

Previous literature focusing on the different national responses to antibiotic resistance highlighted the key risk factors contributing to AMR between developing and developed countries and how each lead to AMR in a different manner. Several AMR contributing factors were found in developing countries which include, poor regulation control of antimicrobial drugs, insufficient monitoring of the emergence of AMR, inappropriate use of antibiotics in clinical settings and the inadequate quality check for antibiotics supplied [27].

Recent studies on the accessibility of antibiotics in low- and middle-income countries found that Vietnam and Bangladesh had the highest proportion of unlicensed locations where antibiotics are administered, with relevant antibiotics frequently found in typical drug stores for mild illnesses, where they are widely available to the general public [28]. Since those communities have such easy access to antibiotics, maintaining this attitude would lead to a number of issues, such as improper use of antibiotics due to a general lack of knowledge on antibiotics and awareness of AMR and with lack of consideration of the quality of the antibiotics distributed. All such factors may contribute to the emergence of AMR.

On the contrary, in developed countries, the risk factors that exist in developing countries may not necessarily apply. These include the excessive use of antimicrobials in agricultural use and over-prescription in clinical settings [27]. Research on this issue presents conflicting findings as a more recent study reported that China, as a developing country, became the top consumer of veterinary antimicrobials in 2017, accounting for up to 45% of global consumption and is estimated to remain the biggest user in 2030. In addition, with evidence that developed countries have reduced their total antimicrobial sales, for example, the UK had a 39.2% decrease from 2015 to 2017 [29]. These results suggested that risk variables in emerging countries are now beginning to overlap with those in developed countries.

There is now a growing body of research that investigates global antibiotic consumption. The Global Research on Antimicrobial Resistance (GRAM) Project, conducted the first known long-term study to estimate the global consumption of antibiotics, which covered 204 nations from years 2000–2018. According to this estimation of the average daily dose, a significant increase of 46% in the global antibiotic consumption rate was observed throughout this period of time [30].

This seminal study through employment of a spatial disparities/geostatistical model, identified large national and subnational variations of antibiotic usage in Low- and Middle-income countries (LMICs), with the lowest levels in sub-Saharan Africa and the highest in eastern Europe and central Asia [30]. The study also showed a global antibiotic consumption rate of 14.3 (95% uncertainty interval 13.2–15.6) defined daily doses (DDD) per 1,000 population per day in 2018 (40.2 [37.2–43.7] billion DDD), an increase of 46% from 9.8 (9.2–10.5) DDD per 1,000 per day in 2000 [30]. There were large increases in the consumption of fluoroquinolones and third-generation cephalosporins in North Africa and Middle East and south Asia [30]. Carbapenem consumption was highest in the high-income region, where it increased from 0.05 to 0.09 DDD per 1,000 per day from 2000 to 2018 [30]. The surge in the misuse of antibiotics has remained the main factor in causing this trend and the emergence of AMR. The characteristic of inappropriate use of antibiotics includes using antibiotic for an insufficient amount of time than specified, treating conditions other than bacterial infection using antibiotics, as well incorrect administration methods and dosage taken [31].

Despite that, critics have also argued that this is not the only problem but an addition to issues of increased “last line antimicrobials” consumption. According to recent research, last-line antibiotics such as polymyxin consumption in humans has increased by 67% in the EU/EEA and these last-line antibiotics are typically prescribed in hospital settings to treat patients suffering from serious infections as a last resort to combat multidrug-resistant bacteria [32]. As a result, the increased consumption of such antimicrobials could eventually induce resistance and paradoxically make serious infectious diseases more difficult-to-treat.

This ongoing pattern has presented a strong correlation between AMR and antibiotic consumption. Several studies have supported this view, including a longitudinal study which reported a significant strong association between the use of antibiotics, particularly carbapenems and carbapenem resistance [33]. Similarly, this trend was supported by another study which also identified a strong correlation between the antibiotic consumed and the prevalence of carbapenem resistance in Gram-negative bacteria [34].

However, issues of the debate are a concern as previous studies have argued that a direct correlation may not be present between antibiotic consumption and AMR since other factors were ignored during the research. Many of these correlation studies were conducted in hospitals where patients are presented with underlying problems, the results of the correlation may be overstated [35]. Further research would be needed to be conducted in this area with a study being more inclusive and not restricted to a specific sector.

Antibiotic usage also influenced AMR in relation to the difference between LMICs and High Income Countries (HICs), resistance maps of global usage of antibiotics were collected worldwide from the years 2000–2015 (Figures 2A, B). A distinct pattern was observed, as seen in Figure 2A, when in 2000, the more developed continents including North America, Europe, and Australia were shown to have the highest overall antibiotics usage. However, compared to Figure 2B with data from 2015, it was observed that usage of antibiotic remains high in Europe, with a slight decrease in North America, in contrast, parts of Africa and Asia have been reported to have increased antibiotic use since 2000 [36].

Since there is evidence of a correlation between the overuse of antibiotics and the development of AMR, reducing antibiotics usage could be a beneficial goal in HICs, with over usage of antimicrobials. In contrast, increasing the accessibility of such antimicrobial medication remains a goal for many LMICs, as the death rate remains high caused by infectious diseases in many LMICs due to the lack of effective antimicrobials access to those in need [37]. In a study with children in Haiti, Kenya, Malawi, Namibia, Nepal, Senegal, Tanzania, and Uganda between May 2006 and December 2016, antibiotics were prescribed to 80.5% of children diagnosed with respiratory illness, 50.1% with diarrhoea, and 28.3% with malaria, where the mean number of antibiotic prescriptions issued to children between birth and age 5 years across the eight countries was 24.5 (95% CI 22.6–26.7), ranging from 7.1 (6.3–7.9) in Senegal to 59.1 (54.1–64.6) in Uganda [38]. The authors indicated that with such high prescription rates for antibiotics, that there was over-prescribing of antibiotics that needs addressing to avoid the emergence of AMR [38].

While there is ongoing research on new antimicrobial treatments, there must be controls and management of the antibiotics including standardisation of quality checks and accessibility of antibiotics. Therefore, improving surveillance programs is urgently required in some LMICs to improve the current state of AMR.

The occurrence of the COVID-19 pandemic in 2020 created an unprecedented scenario for the treatment of suspected or proven bacterial infections with antibiotics. The changing dynamic in the movement of patients within healthcare (community and hospital), largely driven by the patients’ SARS CoV-2 status, combined with reduced diagnostic ability due to redeployment of laboratory staff to SARS CoV-2 testing, resulted in a temporary redefining of “Best Practice” antimicrobial stewardship programmes, due to pandemic-related constraints. A recent study investigating global antibiotic use during the pandemic, through examination of pharmaceutical sales data from 71 countries during the years, 2020–2022, showed that sales of cephalosporins, penicillins, macrolides, and tetracyclines decreased dramatically during April–May 2020, afterwhich there was a gradual rise to nearly pre-pandemic rates through May 2022 [51]. This study calculated that a 10% increase in monthly COVID-19 cases was associated with 0.2%–0.3% higher sales of cephalosporins, 0.2%–0.3% higher sales of penicillins, 0.4%–0.6% higher sales of macrolides, and 0.3% higher sales of all four antibiotics combined per 1,000 people. Geographically, a 10% increase in monthly COVID-19 cases was associated with 0.8%, 1.3%, and 1.5% higher macrolides sales in Europe, North America, and Africa, respectively. The U.S. Centers for Disease Control and Prevention estimates that antibiotic resistance in the United States increased 15% during 2019–2020, leading to 29,400 additional deaths, of which 40% were from hospital-acquired infections [52].

As part of the 2030 Agenda for Sustainable Development, the United Nations has published 17 Sustainable Development Goals (SDGs) including many aspects of societal and human interactions, as illustrated in Figure 4 [53]. One SDG is SDG3–“Good Health and Wellbeing.” Within this, AMR has a named specific inclusion, with indicator 3.d.2, namely, “Percentage of bloodstream infections due to selected antimicrobial-resistant organisms.” The WHO have indicated that AMR impacts seven of the 17 SDGs, as detailed in Figure 5 and these are futher discussed by Jasovský et al. [55], particularly in terms of environmental, social, and economic targets in the SDG framework.

Antimicrobial resistance continues to be a major global public health dilemma of the 21st century. Already this topic is receiving substantial political input from the G7 countries and continues to be on the agenda of numerous political conferences. Adoption of mitigating strategies are beginning to see positive results, with tangible outcomes (see Table 1). However, the consequences of failure to adequately address AMR are profound, with estimations of a return to the pre-antibiotic era, where everyday infections relating to childbirth, surgery and open fractured limbs could be potentially life-threatening. AMR itself represents a microcosm of factors, including social anthropology, civil unrest/war, diasporas, ethnic displacement, political systems, healthcare, economics, societal behaviour both at a population and individual level, health literacy, geoclimatic events, global travel and pharmaceutical innovation and investment, thus finding a solution that adequately addresses AMR and which helps stem further AMR emergence is complicated. Success will involve individuals, communities and nations all working together to ensure that the world continues to possess a sufficient armamentarium of effective antimicrobials that will sustain human and animal health, both now and in the future.